MCID: SCL009
MIFTS: 53

Sclerosing Cholangitis

Categories: Rare diseases, Liver diseases, Gastrointestinal diseases

Aliases & Classifications for Sclerosing Cholangitis

MalaCards integrated aliases for Sclerosing Cholangitis:

Name: Sclerosing Cholangitis 12 72 14
Cholangitis, Sclerosing 41 69
Primary Sclerosing Cholangitis 69
Fibrosing Cholangitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14268
ICD10 32 K83.0
MeSH 41 D015209
UMLS 69 C0008313

Summaries for Sclerosing Cholangitis

MalaCards based summary : Sclerosing Cholangitis, also known as cholangitis, sclerosing, is related to sclerosing cholangitis, neonatal and autoimmune pancreatitis, and has symptoms including icterus An important gene associated with Sclerosing Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Allograft rejection and HTLV-I infection. The drugs Vancomycin and Ceftriaxone have been mentioned in the context of this disorder. Affiliated tissues include liver, eye and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder... more...

Related Diseases for Sclerosing Cholangitis

Diseases in the Sclerosing Cholangitis family:

Cholangitis, Primary Sclerosing Secondary Sclerosing Cholangitis

Diseases related to Sclerosing Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 34.3 CFTR CLDN1 DCDC2
2 autoimmune pancreatitis 31.3 CFTR HLA-DRB1 TNF
3 cholangitis, primary sclerosing 31.3 ABCB4 BPI CFTR CTSG FUT2 GPBAR1
4 burns 30.3 ALB TNF
5 pure red-cell aplasia 30.2 ALB HLA-B HLA-DRB1
6 gastroenteritis 30.0 ALB FUT2 TNF
7 obstructive jaundice 29.9 ALB GPBAR1 TNF
8 psoriatic arthritis 29.8 HLA-B HLA-C HLA-DRB1 TNF
9 autoimmune disease 29.8 CD40LG HLA-B HLA-DRB1 TNF
10 cystic fibrosis 29.7 BPI CFTR CTSG MPO
11 suppurative cholangitis 29.6 ABCB4 MPO TNF
12 liver disease 29.6 ABCB11 ABCB4 ALB TNF
13 churg-strauss syndrome 29.5 CD40LG MPO TNF
14 cholestasis 29.4 ABCB11 ABCB4 NR1I2
15 acquired immunodeficiency syndrome 29.4 ALB CD40LG HLA-B TNF
16 pneumonia 29.3 CD40LG MPO TNF
17 bronchiectasis 29.3 BPI CFTR CTSG MPO
18 celiac disease 1 29.2 ALB CD40LG TNF
19 inflammatory bowel disease 29.2 ALB BPI CTSG HLA-B HLA-DRB1 MPO
20 primary biliary cirrhosis 29.0 ABCB11 ABCB4 ALB CD40LG HLA-DRB1 NR1I2
21 bile duct disease 28.8 ABCB11 ABCB4 ALB GPBAR1 NR1I2
22 biliary tract disease 28.7 ABCB11 ABCB4 ALB GPBAR1 NR1I2
23 cholangitis 28.5 ABCB11 ABCB4 ALB CD40LG CFTR CLDN1
24 intrahepatic cholestasis 28.4 ABCB11 ABCB4 ALB GPBAR1 NR1I2
25 systemic lupus erythematosus 28.4 ALB CD40LG CTSG HLA-DRB1 MPO TNF
26 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 12.7
27 secondary sclerosing cholangitis 12.5
28 igg4-related sclerosing cholangitis 12.2
29 pancreatitis, sclerosing cholangitis, and sicca complex 12.2
30 isolated neonatal sclerosing cholangitis 12.1
31 bile duct carcinoma 11.6
32 cholangiocarcinoma 11.6
33 colitis 10.7
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
35 ulcerative colitis 10.7
36 pancreatitis 10.6
37 postherpetic neuralgia 10.6 HLA-B HLA-DRB1
38 hepatitis 10.5
39 idiopathic inflammatory myopathy 10.5 HLA-B HLA-DRB1
40 biliary cirrhosis, primary, 1 10.5
41 glaucomatocyclitic crisis 10.5 HLA-B HLA-C
42 beryllium disease 10.4 HLA-DRB1 TNF
43 autoimmune hepatitis 10.4
44 pars planitis 10.4 HLA-B HLA-DRB1
45 fibrosis of extraocular muscles, congenital, 1 10.4
46 autoimmune inner ear disease 10.4 MPO TNF
47 chronic beryllium disease 10.4 HLA-DRB1 TNF
48 crohn's disease 10.4
49 pityriasis rosea 10.4 HLA-B HLA-C HLA-DRB1
50 anteroseptal myocardial infarction 10.4 ALB FUT2 HLA-DRB1

Graphical network of the top 20 diseases related to Sclerosing Cholangitis:



Diseases related to Sclerosing Cholangitis

Symptoms & Phenotypes for Sclerosing Cholangitis

UMLS symptoms related to Sclerosing Cholangitis:


icterus

GenomeRNAi Phenotypes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

25 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.8 HLA-C CTSG HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.8 HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.8 HLA-C HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.8 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.8 CTSG
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.8 CTSG HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.8 HLA-B HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.8 CTSG
9 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.8 HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.8 HLA-B HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.8 HLA-B HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.8 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.8 CTSG
14 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.8 HLA-B HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.8 CTSG
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.8 HLA-C
17 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.8 HLA-B HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.8 HLA-B HLA-C
19 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.8 HLA-C

MGI Mouse Phenotypes related to Sclerosing Cholangitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.23 ABCB11 ABCB4 ALB CFTR CTSG GPBAR1

Drugs & Therapeutics for Sclerosing Cholangitis

Drugs for Sclerosing Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vancomycin Approved Phase 4,Phase 3,Phase 1 1404-90-6 14969 441141
2
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
5
Ofloxacin Approved Phase 4 82419-36-1 4583
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
8
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
12 glucocorticoids Phase 4,Phase 1
13 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Hormone Antagonists Phase 4,Phase 1
15 Hormones Phase 4,Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1
17 Immunoglobulins Phase 4,Phase 2,Phase 1
18 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
19 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
20 Antibiotics, Antitubercular Phase 4,Phase 2
21 Antibodies Phase 4,Phase 2,Phase 1
22 Bile Acids and Salts Phase 4,Phase 2,Phase 1
23 Antirheumatic Agents Phase 4,Phase 1,Phase 2
24 Prednisolone acetate Phase 4
25 Renal Agents Phase 4
26 Methylprednisolone acetate Phase 4
27 Methylprednisolone Hemisuccinate Phase 4
28 Topoisomerase Inhibitors Phase 4
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
30 Cytochrome P-450 Enzyme Inhibitors Phase 4
31 Prednisolone hemisuccinate Phase 4
32 Prednisolone phosphate Phase 4
33 Antineoplastic Agents, Hormonal Phase 4
34 Antitubercular Agents Phase 4
35
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3,Phase 1 128-13-2 31401
36
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
37 Antimetabolites Phase 3,Phase 1,Phase 2
38 Cholagogues and Choleretics Phase 2, Phase 3,Phase 1
39 Hypolipidemic Agents Phase 3,Phase 1,Phase 2
40 Lipid Regulating Agents Phase 3,Phase 1,Phase 2
41
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
42
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
43
Curcumin Approved, Investigational Phase 1, Phase 2 458-37-7 969516
44
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
45
Fenofibrate Approved Phase 1, Phase 2 49562-28-9 3339
46
Tretinoin Approved, Investigational, Nutraceutical Phase 2,Phase 1 302-79-4 5538
47 TAK-652 Phase 2
48 2-chloro-3'-deoxyadenosine Phase 2
49 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
50 Dermatologic Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 86)

# Name Status NCT ID Phase Drugs
1 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
3 Leflunomide for Maintenance of Remission in IgG4 Related Disease Recruiting NCT02703194 Phase 4 Prednisone;Leflunomide
4 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Active, not recruiting NCT02464020 Phase 4 Vancomycin
5 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
6 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3 Probiotics
7 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
8 The Effect of Bezafibrate on Cholestatic Itch Recruiting NCT02701166 Phase 3 Bezafibrate;Placebo
9 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Active, not recruiting NCT01802073 Phase 3 Oral Vancomycin
10 Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
11 PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
12 Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
13 Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
14 Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
15 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
16 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine
17 Rituximab in IgG4-RD: A Phase 1-2 Trial Completed NCT01584388 Phase 1, Phase 2 Rituximab
18 Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Recruiting NCT01688024 Phase 2 Mitomycin C;Normal saline
19 A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Recruiting NCT02239211 Phase 2 BTT1023
20 A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Recruiting NCT02978339 Phase 1, Phase 2 Curcumin
21 A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) Recruiting NCT03394781 Phase 2 DUR-928
22 A POC and Dose-Ranging Study of HTD1801 in PSC Patients Recruiting NCT03333928 Phase 2 HTD1801;Placebo
23 An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis Recruiting NCT03359174 Phase 2 All-trans retinoic acid
24 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
25 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Active, not recruiting NCT02424175 Phase 1, Phase 2
26 Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Active, not recruiting NCT02177136 Phase 2 OCA;Placebo
27 Safety, Tolerability, and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Active, not recruiting NCT02943460 Phase 2 GS-9674;Placebo to match GS-9674
28 A Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis Not yet recruiting NCT02780752 Phase 1, Phase 2 hymecromone
29 A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH Not yet recruiting NCT02997878 Phase 1, Phase 2
30 Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC) Terminated NCT00953615 Phase 2 Thalidomide
31 Pilot Study of Fenofibrate for PSC Terminated NCT01142323 Phase 1, Phase 2 fenofibrate
32 The Value of CT Cholangiography in Primary Sclerosing Cholangitis Withdrawn NCT00588458 Phase 2
33 Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) Completed NCT00955149 Phase 1 Erlotinib (Tarceva)
34 Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Completed NCT01322386 Phase 1 Vancomycin
35 Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Completed NCT01088607 Phase 1 ursodeoxycholic acid (UDCA)
36 A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis Completed NCT01085760 Phase 1 Vancomycin;Vancomycin;Metronidazole;Metronidazole;Vancomycin
37 Minocycline in Primary Sclerosing Cholangitis (PSC) Completed NCT00630942 Phase 1 Minocycline
38 A Pilot Study of Xifaxan to Treat Patients With PSC Completed NCT01695174 Phase 1 Xifaxan
39 Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Completed NCT00004842 Phase 1 budesonide
40 Evaluation of DHA for the Treatment of PSC Completed NCT00325013 Phase 1 Docosahexaenoic Acid (DHA)
41 Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis Completed NCT01456468 Phase 1 Oral all-trans retinoic acid (ATRA)
42 A Study of HTD1801 in Healthy Subjects Completed NCT03099603 Phase 1 HTD1801
43 Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging Completed NCT01439620 Phase 1
44 Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT Completed NCT01879735 Phase 1 11C-CSar;ICG
45 Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Recruiting NCT02137668 Phase 1 Oral Vancomycin
46 Treatment of IgG4-Related Disease With Revlimid and Rituximab Recruiting NCT02705638 Phase 1 Rituximab;Lenalidomide
47 A Study Of Ursolic Acid For Primary Sclerosing Cholangitis Withdrawn NCT03216876 Phase 1 Ursolic acid
48 NPD Measurements in PSC Patients Unknown status NCT00476814
49 Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis Unknown status NCT02247622
50 Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy Unknown status NCT01549795 Capecitabine

Search NIH Clinical Center for Sclerosing Cholangitis

Cochrane evidence based reviews: cholangitis, sclerosing

Genetic Tests for Sclerosing Cholangitis

Anatomical Context for Sclerosing Cholangitis

MalaCards organs/tissues related to Sclerosing Cholangitis:

38
Liver, Eye, Skin, Colon, T Cells, Testes, Thyroid

Publications for Sclerosing Cholangitis

Articles related to Sclerosing Cholangitis:

(show top 50) (show all 985)
# Title Authors Year
1
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )
2018
2
The significance of serum IgG<sub>4</sub>and CA19-9, autoantibodies in diagnosis and differential diagnosis of IgG<sub>4</sub>-related sclerosing cholangitis. ( 29272982 )
2018
3
High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. ( 29378311 )
2018
4
Quality of life and primary sclerosing cholangitis: the business of defining what counts. ( 29315689 )
2018
5
Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. ( 29321484 )
2018
6
Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis. ( 29314124 )
2018
7
Localized intrahepatic IgG4-related sclerosing cholangitis (IgG4-SC) as an additional type of IgG4-SC: a systematic analysis of 12 cases. ( 29313399 )
2018
8
Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. ( 29411404 )
2018
9
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. ( 29377235 )
2018
10
Crohn's Disease Behavior and Location is Altered when Associated with Primary Sclerosing Cholangitis. ( 29333790 )
2018
11
Cholestasis after TIPS placement in a patient with primary sclerosing cholangitis: an uncommon complication. ( 29278002 )
2018
12
Lack of Correlation of Liver Tests With Fibrosis Stage at Diagnosis in Pediatric Primary Sclerosing Cholangitis. ( 29356767 )
2018
13
Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study. ( 29301479 )
2018
14
A promising medium-term follow-up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis? ( 29316057 )
2018
15
Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314130 )
2018
16
The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. ( 29435321 )
2018
17
Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. ( 29378308 )
2018
18
Peribiliary Cysts presenting as Primary Sclerosing Cholangitis. ( 29432923 )
2018
19
Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314129 )
2018
20
Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis. ( 28839442 )
2017
21
Novel CLDN1 mutation in ichthyosis-hypotrichosis-sclerosing-cholangitis syndrome without signs of liver disease. ( 28906553 )
2017
22
Secondary sclerosing cholangitis in critically ill patients: current perspectives. ( 28694703 )
2017
23
Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice. ( 28056490 )
2017
24
Secondary sclerosing cholangitis in cardiac surgical patients: A complication with a dismal prognosis. ( 28554673 )
2017
25
Updates on primary sclerosing cholangitis. ( 28079751 )
2017
26
Very Severe Secondary Sclerosing Cholangitis as a Sequela of Influenza. ( 28683859 )
2017
27
Secondary sclerosing cholangitis following cardiac surgery: An uncommon but deadly gastrointestinal complication. ( 28625770 )
2017
28
Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis. ( 29106505 )
2017
29
Impact of Crohn's Disease Duration on the Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. ( 28050039 )
2017
30
Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia. ( 28796833 )
2017
31
Acute-on-chronic hepatitis. A case report of autoimmune hepatitis/primary sclerosing cholangitis/ulcerative colitis overlap syndrome in a 15-year-old patient. ( 28856287 )
2017
32
Isolated IgG4-related sclerosing cholangitis misdiagnosed as malignancy in an area with endemic cholangiocarcinoma: a case report. ( 28202062 )
2017
33
New approach to decrease post-ERCP adverse events in patients with primary sclerosing cholangitis. ( 28791317 )
2017
34
Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. ( 28844951 )
2017
35
Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011. ( 28796371 )
2017
36
Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. ( 28951510 )
2017
37
Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. ( 28951512 )
2017
38
IgG4-related sclerosing cholangitis overlapping with autoimmune hepatitis: Report of a case. ( 28238541 )
2017
39
Primary Hepatic Adenosquamous Carcinoma Associated with Primary Sclerosing Cholangitis. ( 29258074 )
2017
40
NOD2 gene variants confer risk for secondary sclerosing cholangitis in critically ill patients. ( 28765628 )
2017
41
Pregnant Lady With Undiagnosed Hodgkin's Disease Presenting As Secondary Sclerosing Cholangitis. ( 29331005 )
2017
42
A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. ( 28056976 )
2017
43
Endpoints in the design of clinical trials for primary sclerosing cholangitis. ( 28847513 )
2017
44
Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis. ( 28943450 )
2017
45
Case report: A female case of isolated IgG4-related sclerosing cholangitis mimicking cholangiocarcinoma. ( 28422840 )
2017
46
Secondary sclerosing cholangitis in localized hepatobiliary tuberculosis simulating cholangiocarcinoma: a rare case report. ( 29179696 )
2017
47
Primary biliary cholangitis-primary sclerosing cholangitis in an evolving overlap syndrome: A case report. ( 28089354 )
2017
48
Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis: A Case Report and Review of the Literature. ( 29269682 )
2017
49
Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice. ( 28055006 )
2017
50
Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis. ( 27943017 )
2017

Variations for Sclerosing Cholangitis

Expression for Sclerosing Cholangitis

Search GEO for disease gene expression data for Sclerosing Cholangitis.

Pathways for Sclerosing Cholangitis

GO Terms for Sclerosing Cholangitis

Cellular components related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 ABCB11 ABCB4 BPI CD40LG CFTR CLDN1
2 extracellular exosome GO:0070062 9.7 ABCB11 ABCB4 ALB BPI CFTR CTSG
3 azurophil granule lumen GO:0035578 9.63 BPI CTSG MPO
4 recycling endosome membrane GO:0055038 9.58 CFTR HLA-B HLA-C
5 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-B HLA-C HLA-DRB1
6 MHC class I protein complex GO:0042612 9.43 HLA-B HLA-C
7 intercellular canaliculus GO:0046581 9.37 ABCB11 ABCB4
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-B HLA-C HLA-DRB1
9 cell surface GO:0009986 9.17 CD40LG CFTR CTSG HLA-B HLA-C HLA-DRB1
10 integral component of membrane GO:0016021 10.26 ABCB11 ABCB4 BPI CD40LG CFTR CLDN1
11 plasma membrane GO:0005886 10.24 ABCB11 ABCB4 CD40LG CFTR CLDN1 CTSG

Biological processes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.85 BPI CTSG HLA-B HLA-C MPO
2 defense response to bacterium GO:0042742 9.71 BPI CTSG MPO TNF
3 response to lipopolysaccharide GO:0032496 9.67 ABCB4 CLDN1 CTSG MPO
4 interferon-gamma-mediated signaling pathway GO:0060333 9.61 HLA-B HLA-C HLA-DRB1
5 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.52 ABCB11 CFTR
6 response to dexamethasone GO:0071548 9.51 ABCB4 CLDN1
7 xenobiotic transport GO:0042908 9.49 ABCB4 NR1I2
8 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.48 HLA-B HLA-C
9 antigen processing and presentation GO:0019882 9.33 HLA-B HLA-C HLA-DRB1
10 drug export GO:0046618 9.32 ABCB4 NR1I2
11 regulation of immunoglobulin secretion GO:0051023 9.26 CD40LG TNF
12 immune response GO:0006955 9.17 BPI CD40LG CTSG HLA-B HLA-C HLA-DRB1
13 negative regulation of growth of symbiont in host GO:0044130 9.13 CTSG MPO TNF

Molecular functions related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.13 ABCB11 ABCB4 CFTR
2 peptide antigen binding GO:0042605 8.8 HLA-B HLA-C HLA-DRB1

Sources for Sclerosing Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....